Skip to search formSkip to main contentSkip to account menu

amrubicin

Known as: (+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione 
A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

AnthracyclinesAntineoplastic Agents
NCIt Antineoplastic Agent Terminology

Narrower (2)

SM 5887amrubicin hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
7000 Background: Amrubicin (AMR), a 3rd-generation anthracycline and potent topoisomerase II inhibitor, has shown promising… 
2011
2011
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
OBJECTIVE No standard chemotherapy has been established yet for large-cell neuroendocrine carcinoma of the lung. Amrubicin is… 
2006
2006
Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC).
7061 Background: Amrubicin, a totally synthetic 9-amino-anthracycline, has been shown to have excellent antitumor activity as a… 
2006
2006
Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer
Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite… 
2006
2006
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial
SummaryPurpose: Amrubicin is a novel 9-aminoanthracycline. This multicenter phase II study was conducted to evaluate the efficacy… 
2006
2006
Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients
Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non… 
2005
2005
Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer
Purpose: Amrubicin is a novel, totally synthetic 9-aminoanthracycline. The present phase I/II study was performed to define its… 
Highly Cited
2002
Highly Cited
2002
Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells. The anthracycline… 
Review
2001
Review
2001
New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer.
1998
1998
In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite
The tissue distribution of a novel antitumor anthracycline antibiotic, amrubicin, was studied using seven human tumor xenografts… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)